FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Autolus Therapeutics PLC Surges After Blackstone Life Sciences Agreed to Invest Up to $250 Million in the company”
Autolus Therapeutics PLC (NASDAQ: AUTL) surged over 29% in premarket trading after Blackstone Life Sciences signed on to provide the company up to $250 million in equity and product financing.
The investment is set to support Autolus’ advancement of its CD19 CAR T cell investigational therapy product candidate, obe-cel, as well as next generation product therapies of obe-cel in B-cell malignancies.
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
For more information, please visit: Autolus Therapeutics PLC
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.